Published in Afr Health Sci on December 01, 2005
Gender equity and reproductive health. Afr Health Sci (2005) 0.75
[Lung cavities, mycetomas and hemoptysis]. Wien Med Wochenschr (2007) 0.75
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis (2002) 6.13
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Early diagnosis of invasive aspergillosis. Lancet (2000) 2.38
Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol (1999) 2.20
Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. Am J Med (1993) 1.86
Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis (2002) 1.79
Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and review. Medicine (Baltimore) (2000) 1.27
Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation (1997) 1.23
Isolated renal Aspergillus abscess in an AIDS patient with a normal CD4+ cell count on highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis (1999) 0.81
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon (2003) 2.39
HIV counseling and testing practices at an urban hospital in Kampala, Uganda. AIDS Behav (2006) 1.83
Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry (2010) 1.73
Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav (2011) 1.66
HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis (2009) 1.64
Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics. Nature (2006) 1.48
Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples. AIDS (2010) 1.37
Pattern of neuropsychological performance among HIV positive patients in Uganda. BMC Neurol (2007) 1.35
Resurrecting the triple threat: academic social responsibility in the context of global health research. Clin Infect Dis (2009) 1.29
The academic alliance for AIDS care and prevention in Africa. Acad Med (2008) 1.27
Evaluation of a low-cost method, the Guava EasyCD4 assay, to enumerate CD4-positive lymphocyte counts in HIV-infected patients in the United States and Uganda. J Acquir Immune Defic Syndr (2006) 1.25
The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci (2008) 1.25
Reducing the burden of sexually transmitted infections in resource-limited settings: the role of improved diagnostics. Nature (2006) 1.13
Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PLoS One (2009) 1.11
Meningitis caused by Streptococcus suis serotype 14, North America. Emerg Infect Dis (2009) 1.11
Total lymphocyte count of 1200 is not a sensitive predictor of CD4 lymphocyte count among patients with HIV disease in Kampala, Uganda. Afr Health Sci (2004) 1.10
The medical management of central nervous system infections in Uganda and the potential impact of an algorithm-based approach to improve outcomes. Int J Infect Dis (2007) 1.10
Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care (Chic) (2008) 1.07
HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy. J Acquir Immune Defic Syndr (2016) 1.02
Advances in clinical education: a model for infectious disease training for mid-level practitioners in Uganda. Int J Infect Dis (2012) 1.02
Measuring the outcomes of a comprehensive HIV care course: pilot test at the Infectious Diseases Institute, Kampala, Uganda. J Acquir Immune Defic Syndr (2006) 1.01
An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda. J Acquir Immune Defic Syndr (2014) 0.98
Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. AIDS (2014) 0.97
Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. AIDS (2014) 0.96
Emergence of quinolone resistance and cephalosporin MIC creep in Neisseria gonorrhoeae isolates from a cohort of young men in Kisumu, Kenya, 2002 to 2009. Antimicrob Agents Chemother (2011) 0.96
Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr (2004) 0.96
The liver in HIV in Africa. Antivir Ther (2005) 0.94
Toll-like receptor polymorphism associations with HIV-1 outcomes among sub-Saharan Africans. J Infect Dis (2013) 0.91
Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology (2012) 0.91
Treatment of HIV/AIDS: do the dilemmas only increase? JAMA (2004) 0.89
Challenges in diagnosis, treatment and follow-up of patients presenting with central nervous system infections in a resource-limited setting. Mcgill J Med (2006) 0.89
Clinical presentation and aetiologies of acute or complicated headache among HIV-seropositive patients in a Ugandan clinic. J Int AIDS Soc (2009) 0.88
Evaluation of Dynabeads and Cytospheres compared with flow cytometry to enumerate CD4+ T cells in HIV-infected Ugandans on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 0.88
Diagnostic challenges of sexually transmitted infections in resource-limited settings. Future Microbiol (2009) 0.85
Functional adrenal insufficiency among critically ill patients with human immunodeficiency virus in a resource-limited setting. Afr Health Sci (2007) 0.83
First report of Actinobaculum schaalii urinary tract infection in North America. Diagn Microbiol Infect Dis (2010) 0.82
The prevalence and causes of visual loss among HIV-infected individuals in Uganda. J Acquir Immune Defic Syndr (2010) 0.82
Response to Ronald Gray, Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda ( 2000, 14:2371-2381). AIDS (2002) 0.81
Disease diagnosis in primary care in Uganda. BMC Fam Pract (2014) 0.81
Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. AIDS (2016) 0.80
Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr (2016) 0.80
Strengthening the "Viral Failure Pathway": Clinical Decision and Outcomes of Patients With Confirmed Viral Failure in a Large HIV Care Clinic in Uganda. J Acquir Immune Defic Syndr (2015) 0.78
Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study. J Acquir Immune Defic Syndr (2016) 0.78
Mortality and immunological recovery among older adults on antiretroviral therapy at a large urban HIV clinic in Kampala, Uganda. J Acquir Immune Defic Syndr (2014) 0.78
Correction: Improving Facility Performance in Infectious Disease Care in Uganda: A Mixed Design Study with Pre/Post and Cluster Randomized Trial Components. PLoS One (2016) 0.75
Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection. J Acquir Immune Defic Syndr (2016) 0.75
Variants in host viral replication cycle genes are associated with heterosexual HIV-1 acquisition in Africans. J Acquir Immune Defic Syndr (2014) 0.75
Medication Sharing is Rare among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention. J Acquir Immune Defic Syndr (2017) 0.75
The Effect of Oral Pre-Exposure Prophylaxis on the Progression of HIV-1 Seroconversion. AIDS (2017) 0.75